Personal care treatments

Biofrontera to present treatments for actinic keratoses and impetigo at the American Academy 2022… | Your money

The company will have a strong on-site presence at the world’s largest scientific conference for dermatologists, with around 10,000 healthcare professionals expected to attend

WOBURN, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatology products, today announced that it will host a booth showcasing its innovation, approved by the FDA products at the 2022 Annual Meeting of the American Academy of Dermatology (AAD) to be held March 25-29, 2022 at the Boston Convention and Exhibition Center.

“We look forward to a strong presence at the largest and most prestigious dermatology conference of the year, following the encouraging momentum of our clinical studies and our commercial footprint. We anticipate a well-attended booth and look forward to connecting with dermatologists, practitioners and dermatology-focused service providers as we grow our trusted brands. Showcasing our portfolio on the world’s premier stage of the dermatology community provides us with tremendous exposure and facilitates our ability to demonstrate the benefits of photodynamic therapy (PDT) for the treatment of actinic keratoses (AK), one of the skin conditions most common pre-cancerous diseases,” said Erica Monaco, CEO of Biofrontera Inc.

Members of the Biofrontera Inc. management team, including Ms. Monaco and Hermann Lübbert, Executive Chairman of Biofrontera Inc., will be on hand to meet with academic and clinical dermatologists, potential customers and key opinion leaders from the industry. The Biofrontera Inc. booth (#469) will feature educational and marketing information about its products, including the FDA-approved lead drug Ameluz® (aminolevulinic acid hydrochloride gel, 10%), which is used in combination with the series of RhodoLED® lamps for the treatment of AK, and the topical antibiotic Xepi® (ozenoxacin cream, 1%), approved by the FDA for the treatment of impetigo. Working with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.

The AAD Annual Meeting is the world’s largest scientific meeting for dermatologists, with an average attendance of approximately 18,000 people, including approximately 10,000 medical personnel.

About Biofrontera Inc.

Biofrontera Inc. is a US-based biopharmaceutical company that markets a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are precancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Forward-looking statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the expected start and closing dates of transactions. We have based these forward-looking statements on our current expectations and projections regarding future events, however, actual results or events could differ materially from the plans, intentions and expectations disclosed or implied by the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any change in the Company’s relationship with the Licensor; the Company’s ability to achieve and maintain profitability; whether the current global supply chain disruptions will impact the Company’s ability to obtain and distribute its licensed products; changes in healthcare provider practices, including any changes in coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in initiating and conducting clinical trials; availability and timing of clinical trial data; whether the results of prior clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and marketing authorization applications; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is in line with the Company’s expectations; whether the Company will be able to successfully transition to a public company operating independently of Biofrontera AG; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and the need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which may be obtained at the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made and reflect management’s current estimates, projections, expectations and beliefs. The company does not plan to update these forward-looking statements and expressly disclaims any obligation to update the information contained in this press release, except as required by law.

contacts:

Biofrontera Inc. Anke zur Mühlen +1 781 486 1539 [email protected]

LHA Investor Relations Tirth T. Patel +1 212 201 6614 [email protected]

# # #

Copyright 2022 GlobeNewswire, Inc.